Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

被引：0
作者：
Steven B. Zeliadt
David F. Penson
机构：
[1] Fred Hutchinson Cancer Research Center,Division of Public Health Sciences
[2] Keck School of Medicine,Departments of Urology and Preventive Medicine
[3] University of Southern California,undefined
[4] Departments of Urology,undefined
来源：
PharmacoEconomics | 2007年 / 25卷
关键词：
Prostate Cancer; Androgen Deprivation Therapy; Flutamide; Advanced Prostate Cancer; Goserelin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease. We identified 58 articles addressing economic issues related to metastatic prostate cancer.
引用
收藏
页码：309 / 327
页数：18
相关论文
共 227 条
  • [1] Jemal A(2006)Cancer statistics, 2006 CA Cancer J Clin 56 106-130
  • [2] Siegel R(2005)20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2095-2101
  • [3] Ward E(2003)Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer Urology 62 866-871
  • [4] Albertsen PC(1941)Studies on prostatic cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293-297
  • [5] Hanley JA(2002)Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 168 9-12
  • [6] Fine J(2005)Androgen deprivation therapy for prostate cancer JAMA 294 238-244
  • [7] Khan MA(2004)American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Onc 22 2927-2941
  • [8] Partin AW(2002)Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 3972-3982
  • [9] Mangold LA(1996)Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756-164
  • [10] Huggins C(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
12345678910